Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer;Indications, contre-indications, résultats attendus et choix de la chimiothérapie néoadjuvante du cancer du sein opérable

Bulletin du Cancer

Volumn 93, Issue 11, 2006, Pages 1121-1129

  Mouret Reynier, Marie Ange ^a   Abrial, Catherine ^a   Leheurteur, Marianne ^a   Durando, Xavier ^a   Van Praagh, Isabelle ^a   Gimbergues, Pierre ^a   Achard, Jean Louis ^a   Ferrière, Jean Pierre ^a   Cure, Hervé ^a   Chollet, Philippe ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

Contra indications; Indications; Neoadjuvant chemotherapy; Operable breast cancer

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PRACTICE GUIDELINE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33845959501     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2006.0161     Document Type: Article

References (64)

1. De Lena M, Variai M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981; 4: 229-36.
2. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507-16.
3. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast conservating treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66: 119-29.
4. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-71.
5. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10: 1014-24.
6. Viens P, Palangié T, Janvier M, et al. Fist line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (Pegase 02 program). Br J Cancer 1999; 81: 449-56.
7. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
8. Smith IE, Jones AL, O'Brien ME, et al. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993; 29A: 592-5.
9. Smith GA, Henderson IC. High dose chemotherapy (HDC) with Autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. Important advances in oncology 1995. In: De Vita VT, Hellman S, Rosenberg SA, eds. Philadelphia: JB Lippincott Company, 1995.
10. Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in inoperable breast cancer. Eur J Cancer 1997; 33: 862-6.
11. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings form National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-93.
12. Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 1991; 2: 347-54.
13. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-52.
14. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenaupausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A: 645-52.
15. Van Praagh I, Curé H, Leduc B, Charrier S, Le Bouëdec G, Achard JL, et al. Efficacy of primary chemotherapy regimen combining Vinorelbine, Epirubicine and Methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. Oncologist 2002; 7: 418-23.
16. Mouret-Reynier MA, Abrial C, Ferrière JP, Amat S, Curé H, Kwiatkowski F, et al. Neoadjuvant FEC 100 for operable breasr cancer: Eight-year experience at Centre Jean-Perrin. Clin Breast Cancer 2004; 5: 303-7.
17. Petit T, Wilt M, Velten M, Million R, Rodier JF, Borel C, et al. Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205-11.
18. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180: 297-306.
19. Luporsi E, Vanlemmens L, Coudert B, et al. 6 cycles of FEC 100 vs 6 cycles of epirubicin docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: preliminary results of a randomized phase II of Girec S01. Proc Am Soc Clin Oncol 2000; 19: 92a; (abstr 355).
20. Belembaogo E, Feillel V, Chollet P, Curé H, Verrelle P, Kwiatkowski F, et al. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 1992; 28: 896-900.
21. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-8.
22. Curé H, Charrier S, Ferrière JP, et al. Chimiothérapie première dans les cancers du sein opérables supérieurs à 3 cm: résultats de 3 protocoles. Bull Cancer 1997; 84: 31-4.
23. Smith IE, A'Hern R, Coombes G, Hickish T, O'Brien M, Robinson A, et al. A randomised neoadjuvant chemotherapy trial of vinorelbine/epirubicin (VE) vs standard doxorubicin/cyclophosphamide (DC) in patients with ≥ 3 cm diameter operable breast cancer (topic 2). Proc Annu Meet Am Soc Clin Oncol 2003; 22: 21; (abstract 83).
24. Barni S, Visini M, Piazza E, Lonta MT, Arnoldi E, Ardizzoia A, et al. Cisplatin-epirubicin-vinorelbine (PEV): a new neoadjuvant chemotherapy for stage T2-3/N0-2 breast cancer patients pts). Proc Annu Meet Am Soc Clin Oncol 2002; 21: 37b; (abstract 1961).
25. Watatani M, Ueda K, Daito K, Azumi T, Hirai T, Yamato M, et al. Clinical experience of weekly paclitaxel-based treatment as preoperative chemotherapy for patients with primary breast cancer. Breast Cancer 2004; 11: 187-93.
26. Diéras V, Fumoleau P, Romieu G, et al. A randomized parallel study of doxorubicin/taxol (AT) and doxorubicine/cyclophosphamide (AC) as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 1998; 50: 233; (abstract 25).
27. Fumoleau P, Tubiana-Hulin M, Romieu G, Namer M, Delva R, Guastalla JP, et al. A randomized phase II study of 4 or 6 cycles of adriamycin/taxol (paclitaxel) as neoadjuvant treatment of breast cancer. Ann Oncol 2001 (abstract 508).
28. Abrial C, Van Praagh I, Delva R, et al. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist 2005; 10: 242-9.
29. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003; 88: 1339-45.
30. Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003; 9: 686-92.
31. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12: 320-7.
32. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, et al. Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 3(Suppl 2): S69-S74.
33. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast an Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-74.
34. Von Minckwitz G, Raab G, Schuette M et al. Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy in operable breast cancer: primary endpoint analysis of the Geparduo study. Proceedings ASCO 2002 (abstract 168).
35. Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the Geparduo study of the German Breast Group. J Clin Oncol 2005; 23: 2676-85.
36. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002; 3: 137-44.
37. Hurley J, Franco S, Velez P et al. Primary therapy with herceptin, taxotere and cisplatin in locally advanced and inflammatory breast cancer. Proceedings ASCO 2001 (abstract 1871).
38. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
39. Coudert BP, Arnould L, Moreau L, et al. Pre-operative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006; 17: 409-14.
40. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
41. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005; 23: 8331-9.
42. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998; 4: 230-6.
43. Pierga JY, Mouret E, Laurence V, Dieras V, Savigioni A, Beuzeboc P, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer, the role of clinical response. Eur J Cancer 2003; 39: 1089-96.
44. Amar S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, Van Praagh I, et al. Scarff-Bloom-Richardson (SBR)grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002; 20: 791-6.
45. Vincent-Salomon A, Carton M, Freneaux P, Palangie T, Beuzeboc P, Mouret E, et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 2000; 36: 586-91.
46. Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002; 94: 3107-14.
47. Mathieu MC, Llombart-Cussac A, Spielmann M, Koscielny S, Travalgli JP, Contesso G. Invasive lobular carcinoma of the breast treated by preoperative chemotherapy. Arch Anat Cytol Path 1988; 46: 308.
48. MacGrogan G, Pallud C, Simonie-Lafontaine J, Sagan C, Verrielle V, Antoine M, et al. Pathological and clinical predictors for response to neoadjuvant chemotherapy in breast cancer. Mod Pathol 2003; 16: 162-39A.
49. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88: 406-12.
50. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267-73.
51. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3: 593-600.
52. Remvikos Y, Mosseri V, Asselain B, Fourquet A, Durand JC, Pouillart P, et al. S-phase fractions of breast cancer predict overall and post-relapse survival. Eur J Cancer 1997; 33: 581-6.
53. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000; 89: 2145-52.
54. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005; 92: 147-55.
55. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996; 74: 1458-65.
56. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: 27-33.
57. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003; 22: 1319-25.
58. Sjöström J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000; 6: 3103-10.
59. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6: 2751-8.
60. Jacquemier J, Ginestier C, Charafe-Jauffret E, Bertucci F, Bege T, Geneix J, et al. Petit mais à haut débit ou comment le «Tissue-microarrays» est devenu l'outil fétiche des pathologistes et des chercheurs. Ann Pathol 2003; 23: 623-32.
61. Chang J, Wooten E, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-9.
62. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22: 2284-93.
63. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: (Epub ahead of print).
64. Ginestier C, Charafe-Jauffret E, Bertucci F, et al. Distinct and complementary information provided by use of tissue and DNA microarrays int he study of breast tumor markers. Am J Pathol 2002; 161: 1223-33.